Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial

2018 Gastrointestinal Cancers Symposium
Tweet this page

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).

Jun

Today In Oncology

Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%

Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients

Total Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma

ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy

FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer

;